Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Bioverativ Inc (NASDAQ: BIVV) acted responsibly on behalf of investors’ profitability in the planned sale to Sanofi (NYSE: SNY).

On January 22, 2018, Bioverativ Inc (NASDAQ: BIVV) and Sanofi (NYSE: SNY) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Sanofi will offer Bioverativ shareholders $105.00 per share in cash for all outstanding shares.    

Based in Waltham, Massachusetts, and founded in 2016 Bioverativ Inc a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan.

The investigation focuses on whether NASDAQ: BIVV investors received the highest price and whether the directors of Bioverativ Inc acted in the best interest of Bioverativ Inc company and its shareholders.   

 If you purchased Bioverativ Inc (NASDAQ: BIVV) prior to January 22, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185